Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Dopamine transporter (DAT), encoded by the SLC6A3 gene, is a membrane-spanning protein primarily responsible for the reuptake of dopamine from the synaptic cleft into presynaptic neurons (UniProt: P23975). By clearing dopamine from the synapse, DAT serves as the principal regulator of the duration and intensity of dopaminergic neurotransmission, which is vital for motor control, motivation, and reward-seeking behavior (StatPearls: Physiology, Dopamine Transporter). Dysregulation of DAT expression or function is implicated in several neuropsychiatric conditions, most notably Attention-Deficit Hyperactivity Disorder (ADHD) and Parkinson's disease, where DAT density is often used as a diagnostic biomarker (PubMed: 24953830). Many pharmacological agents target DAT, including psychostimulants like methylphenidate and cocaine, which inhibit the transporter to increase extracellular dopamine levels (PubChem: CID 2771). However, the pairing of DAT with escitalopram is technically incorrect; escitalopram is a selective serotonin reuptake inhibitor (SSRI) with extremely high affinity for the serotonin transporter (SERT) but negligible affinity for DAT (Meyer et al., 2004). Therefore, while DAT is a significant therapeutic target, it is not the target through which escitalopram exerts its primary antidepressant effects.
Inhibition of dopamine reuptake from the synaptic cleft into the presynaptic neuron, thereby increasing the concentration and duration of dopamine signaling (StatPearls: Physiology, Dopamine Transporter).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dopamine transporter (DAT) (DAT).